Get the Stockscreener App
135.35
0.64%
-1.09
Illumina Inc stock is traded at $135.35, with a volume of 565.01K.
It is down -0.64% in the last 24 hours and up +11.13% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$136.44
Open:
$136.19
24h Volume:
565.01K
Relative Volume:
0.32
Market Cap:
$20.70B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
17.14
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
+5.12%
1M Performance:
+11.13%
6M Performance:
+53.82%
1Y Performance:
-7.42%
1-Day Range:
$134.64
$137.09
1-Week Range:
$126.44
$137.09
52-Week Range:
$68.70
$153.06
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
135.47 | 20.85B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
573.46 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
229.19 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
700.44 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
140.85 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
223.24 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
DNA Computing Market - GlobeNewswire Inc.
Your lab’s new best friend for scalable proteomics: Illumina Protein Prep - Illumina
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually - marketscreener.com
Illumina invests in MyOme to advance AI-driven genomic health models By Investing.com - Investing.com India
Illumina (NASDAQ: ILMN) invests in MyOme to launch AI-driven WGS trial in 2026 - Stock Titan
Stifel reiterates Buy rating on Illumina stock, cites multiple growth levers - Investing.com Australia
Leadership Perspectives: Illumina leads the industry in genomic AI - Illumina
Does Surging Genomics Consumables Demand Reshape The Bull Case For Illumina’s Recurring Revenue Engine (ILMN)? - Yahoo Finance
Zacks.com featured highlights include Illumina, Commercial Metals and Newmont - Nasdaq
Precision oncology at your community’s doorstep - Illumina
Illumina Inc ILU Stock Analysis and ForecastAI-Driven Market Analysis & Free Lightning Fast Capital Gains - earlytimes.in
Illumina (ILMN): Assessing Valuation After a Quiet Share Price Rebound - Yahoo Finance
Illumina (NASDAQ:ILMN) Upgraded at Zacks Research - MarketBeat
Illumina at the 2025 China International Import Expo (CIIE) - Illumina
Will Illumina Inc. (ILU) stock draw ESG focused funds2025 Top Decliners & Smart Swing Trading Techniques - Newser
How Illumina Inc. (ILU) stock reacts to fiscal policiesPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - Newser
AI in Biotech Market Is Booming Worldwide | NVIDIA, Illumina - openPR.com
Epigenetics Market size to reach $8.63 Billion by 2035 | Key - openPR.com
American Century Companies Inc. Sells 32,763 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Schroder Investment Management Group Raises Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Will Illumina Inc. (ILU) stock keep high P E multiplesTrade Signal Summary & Safe Capital Allocation Plans - Newser
Can Illumina Inc. (ILU) stock sustain revenue momentumJuly 2025 Setups & Entry Point Confirmation Signals - Newser
Korea Investment CORP Reduces Position in Illumina, Inc. $ILMN - MarketBeat
Why Illumina Inc. (ILU) stock fits value portfoliosOil Prices & Fast Exit/Entry Strategy Plans - Newser
Genetic testing transformed her cancer care—and her family tree - Illumina
Illumina, Inc. $ILMN Stake Lifted by Spyglass Capital Management LLC - MarketBeat
Illumina, Inc.: Financial Data Forecasts Estimates and Expectations | ILMN | US4523271090 - marketscreener.com
Illumina, Inc.: Target Price Consensus and Analysts Recommendations | ILMN | US4523271090 - marketscreener.com
Skandinaviska Enskilda Banken AB publ Buys 6,800 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ILMN | US4523271090 - marketscreener.com
State Board of Administration of Florida Retirement System Purchases 2,240 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc.: Dividend historical data and projections - marketscreener.com
Russell Investments Group Ltd. Has $19.79 Million Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
ILMN: Static price chart | Illumina, Inc. | US4523271090 - marketscreener.com
Why global investors buy Illumina Inc. (ILU) stockJuly 2025 Sentiment & Verified Momentum Watchlists - Newser
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
Prudential Financial Inc. Cuts Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Stock Position Lifted by JPMorgan Chase & Co. - MarketBeat
Neuberger Berman Group LLC Purchases 31,438 Shares of Illumina, Inc. $ILMN - MarketBeat
Quadrant Capital Group LLC Buys 17,618 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina’s China Setback Leaves A Discounted Genomics Leader - Finimize
Illumina, Inc. $ILMN Shares Purchased by Coldstream Capital Management Inc. - MarketBeat
Illumina, Inc. Stock (ILMN) Opinions on Strategic Growth and Market Expansion - Quiver Quantitative
Gross margin % of Illumina, Inc. – SIX:ILMN.USD - TradingView
Will Illumina Inc. stock outperform international peersTrade Risk Report & Free Fast Entry Momentum Trade Alerts - BỘ NỘI VỤ
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Illumina Inc. stock undervalued vs historical averagesTrend Reversal & Fast Moving Trade Plans - BỘ NỘI VỤ
DNA Sequencing Market to Hit US$ 51.31 Billion by 2034 at 14.9% - openPR.com
When a worldwide community comes together - Illumina
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):